ÌÇÐÄvlog´«Ã½

Morphine Market Size (2024 - 2029)

The morphine market is projected to experience significant growth over the forecast period, driven by an increasing prevalence of chronic pain and orthopedic diseases, as well as a rising elderly population. The demand for pain management solutions, particularly in palliative care, has surged, partly due to the impacts of the COVID-19 pandemic. Despite challenges such as prescription drug abuse, the market is recovering and expanding, supported by the resumption of manufacturing and the global need for effective pain management therapies.

Market Size of Morphine Industry

Morphine Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 30.46 Billion
Market Size (2029) USD 44.42 Billion
CAGR (2024 - 2029) 7.85 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Morphine Market Analysis

The Morphine Market size is estimated at USD 30.46 billion in 2024, and is expected to reach USD 44.42 billion by 2029, growing at a CAGR of 7.85% during the forecast period (2024-2029).

The COVID-19 pandemic significantly impacted the morphine market. As per the World Health Organization (WHO), chronic pain was one of the hardest-hit areas affected by the COVID-19 pandemic, leaving many patients overburdened with their chronic pain and delays in their ongoing treatments. According to a study published in Nature Journal in January 2021, opioid drug demand during the pandemic increased by approximately 84%.

Hence, the demand for pain medications, such as opioid drugs, including morphine, greatly increased over the pandemic. Thus, COVID-19 had a significant impact on the studied market's growth. However, the market is currently recovering well owing to the resumption of manufacturing plants, and it is expected to witness a similar trend over the coming years.

The major factors contributing to the growth of the market are the rising prevalence of orthopedic diseases and chronic pain, the increase in palliative care facilities, and the rise in the usage of morphine for pain management.

Morphine is considered one of the most effective drugs for the management of pain. Moreover, their use in the management of severe pain and chronic pain, which are associated with advanced medical illnesses, is considered standard practice in most parts of the world. Furthermore, the rising occurrence of orthopedic disorders, such as arthritis, elbow pain, fibromyalgia, and osteoporosis, is the primary factor responsible for the rising growth of the morphine market.

According to WHO data updated in July 2022, musculoskeletal diseases (MSD) are the main cause of disability across the globe, having affected 1.71 billion people globally in 2021. Musculoskeletal conditions are one of the leading contributors to disability worldwide, thereby driving the need for its therapeutics, which in turn is boosting the morphine market towards growth during the study period.

Further, the elderly population is more susceptible to osteoarthritis diseases and chronic pain, and an increasingly elderly population is expected to propel the growth of the market. The United States accounts for the increasing number of individuals suffering from pain. For instance, the Journal of Pain and Palliative Therapy, 2021 accounts that approximately 20.28% of the United States population is suffering from chronic pain and 5% of this population comprises adults who are suffering from high-impact chronic pain. Therefore, with the increasing prevalence of the population suffering from chronic pain in the United States rapidly drives its market for morphine over the forecast period.

Moreover, the growing geriatric population are further expected to increase the demand for morphine globally due to high prevalence of musculoskeletal and other pain related disorders in elderly population. For instance, according to the World Population Prospectus 2022 report published by the United Nations in 2022, the share of people aged 65 years and more in the global population was projected to increase from 10% in 2022 to over 16% by 2050. Also, as per the same source, population growth at older ages is driven by lower mortality and increased survival, and a sustained drop in the fertility level causes an upward shift in the population age distribution.

Thus, due to the above-mentioned factors, the studied market is expected to be significantly driven during the study period. However, prescription drug abuse and risk factors associated with morphine are expected to hinder the growth of the studied market during the study period.

Morphine Industry Segmentation

As per the scope of the report, morphine is an analgesic and narcotic drug obtained from opium for the treatment of moderate to severe pain. 

The Morphine Market is Segmented by Dosage Form (Injection, Oral Tablets, and Other Dosage Forms), Application (Pain Management (Cancer Pain, Neuropathic Pain, Osteoarthritis Pain, and Other Pain Management), Diarrhea Suppressant, Cold and Cough Suppressant, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market size in value terms in USD for all the abovementioned segments.

By Dosage Form
Injection
Oral Tablets
Other Dosage Forms
By Application
Pain Management
Cancer Pain
Neuropathic Pain
Osteoarthritis Pain
Other Pain Managements
Diarrhea Suppressant
Cold and Cough Suppressant
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Morphine Market Size Summary

The morphine market is poised for significant growth over the forecast period, driven by the increasing prevalence of chronic pain and orthopedic diseases, alongside the rising demand for palliative care. The COVID-19 pandemic had a profound impact on the market, as it heightened the demand for pain management medications, including morphine, due to delays in treatments and the exacerbation of chronic pain conditions. As manufacturing operations resume and healthcare systems stabilize, the market is expected to recover and continue its upward trajectory. The effectiveness of morphine in managing severe and chronic pain, particularly in advanced medical conditions, underscores its critical role in pain management globally. The growing elderly population, particularly those susceptible to musculoskeletal disorders, further propels the market, as does the increasing incidence of conditions such as arthritis and cancer, which necessitate effective pain relief solutions.

Regionally, North America is anticipated to lead the market growth, supported by a robust healthcare infrastructure, a high prevalence of chronic diseases, and favorable government policies. The United States, in particular, is a significant contributor to the market due to its large patient base and developed healthcare system. The market's competitive landscape is characterized by the presence of major players who are actively engaging in partnerships and acquisitions to expand their global footprint. Despite the promising growth prospects, challenges such as prescription drug abuse and the associated risks of morphine use pose potential hurdles. Nonetheless, the ongoing awareness initiatives and research partnerships aimed at addressing the opioid crisis are expected to bolster the market's expansion during the study period.

Explore More

Morphine Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Orthopedic Diseases and Chronic Pain

      2. 1.2.2 Increasing Palliative Care Facilities

    3. 1.3 Market Restraints

      1. 1.3.1 Prescription Drug Abuse

      2. 1.3.2 Risk Factors Associated With Intake of Morphine

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - in USD Million)

    1. 2.1 By Dosage Form

      1. 2.1.1 Injection

      2. 2.1.2 Oral Tablets

      3. 2.1.3 Other Dosage Forms

    2. 2.2 By Application

      1. 2.2.1 Pain Management

        1. 2.2.1.1 Cancer Pain

        2. 2.2.1.2 Neuropathic Pain

        3. 2.2.1.3 Osteoarthritis Pain

        4. 2.2.1.4 Other Pain Managements

      2. 2.2.2 Diarrhea Suppressant

      3. 2.2.3 Cold and Cough Suppressant

      4. 2.2.4 Other Applications

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East & Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East & Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Morphine Market Size FAQs

The Morphine Market size is expected to reach USD 30.46 billion in 2024 and grow at a CAGR of 7.85% to reach USD 44.42 billion by 2029.

In 2024, the Morphine Market size is expected to reach USD 30.46 billion.

Morphine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)